Show 10 5 10 15 20 50 100 250 Sort by year (new to old) Actions News feed Embed this list Save this search Mark all Export Your filters: cql: author="RAPOSO, J" or (type exact bookEditor and editor="RAPOSO, J") Mark journalArticle A1 Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study A Chanan-Khan, P Cramer, F Demirkan, G Fraser, RS Silva, S Grosicki, A Pristupa, A Janssens, J Mayer, NL Bartlett, et al. (2016) LANCET ONCOLOGY. 17(2). p.200-211 Mark conference C3 Phase 2 studies of immunochemotherapy +/- bortezomib (VC) in newly diagnosed non-germinal center B-cell-like (GCB) DLBCL: rapid prospective identification of non-GCB patients (PTS) Fritz Offner (UGent) , B Ferhanoglu, JA Reeves, HS Eom, K Doner, J Raposo, IW Flinn, C Suh, NM Chowhan, S Prasad, et al. (2011) ANNALS OF ONCOLOGY. 22(suppl. 4). p.225-225 Mark conference C3 Mabthera (Rituximab) plus CVP chemotherapy for first-line treatment of stage III/IV follicular non-Hodgkin's lymphoma (NHL): Confirmed efficacy with longer follow-up P SOLAL-CELIGNY, K IMRIE, A BELCH, KS ROBINSON, D CUNNINGHAM, A RUEDA, J CATALANO, Fritz Offner (UGent) , J WALEWSKI, J RAPOSO, et al. (2005) BLOOD. 106(11). Mark journalArticle A1 CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma R MARCUS, K IMRIE, A BELCH, D CUNNINGHAM, E FLORES, J CATALANO, P SOLAL-CELIGNY, Fritz Offner (UGent) , J WALEWSKI, J RAPOSO, et al. (2005) BLOOD. 105(4). p.1417-1423 Mark conference C3 CVP plus rituximab compared to CVP alone in previously untreated patients with follicular lymphoma: Impact of baseline prognostic factors K IMRIE, A BELCH, R PETTENGELL, A RUEDA, J MCKENDRICK, P SOLAL-CELIGNY, Fritz Offner (UGent) , I BENCE-BUCKLER, J WALEWSKI, J RAPOSO, et al. (2005) ANNALS OF ONCOLOGY. 16. p.109-110 Mark conference C3 An international multi-centre, randomized, open-label, phase III trial comparing rituximab added to CVP chemotherapy to CVP chemotherapy alone in untreated stage III/IV follicular non-Hodgkins lymphoma R MARCUS, K IMRIE, A BELCH, D CUNNINGHAM, E FLORES, J CATALANO, P SOLAL-CELIGNY, Fritz Offner (UGent) , J WALEWSKI, J RAPOSO, et al. (2003) BLOOD. 102(11).